ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9642
-0.11%
Brent Oil
83.145
0.02%
Bitcoin
64,139.18
0.22%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. ChemoCentryx Inc (CCXI)

  7. ChemoCentryx Inc (CCXI) Noticias

CCXI

ChemoCentryx (CCXI)

ChemoCentryx Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CCXI
FechaHoraFuenteTítuloSímboloCompañía
24/10/202218:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CCXIChemoCentryx Inc
20/10/202208:28Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:CCXIChemoCentryx Inc
20/10/202208:27Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:CCXIChemoCentryx Inc
20/10/202208:20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CCXIChemoCentryx Inc
20/10/202208:05PR Newswire (US)AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYXNASDAQ:CCXIChemoCentryx Inc
20/10/202207:41Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:CCXIChemoCentryx Inc
17/10/202207:30GlobeNewswire Inc.ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual MeetingsNASDAQ:CCXIChemoCentryx Inc
07/10/202215:36Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:CCXIChemoCentryx Inc
05/10/202207:30GlobeNewswire Inc.ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:CCXIChemoCentryx Inc
14/09/202216:32Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:CCXIChemoCentryx Inc
12/09/202210:14Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CCXIChemoCentryx Inc
31/08/202216:08Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:CCXIChemoCentryx Inc
24/08/202207:30GlobeNewswire Inc.ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical ConferencesNASDAQ:CCXIChemoCentryx Inc
09/08/202208:40TipRanksAnalysts Offer Insights on Healthcare Companies: ChemoCentryx (CCXI) and ATI Physical Therapy (ATIP)NASDAQ:CCXIChemoCentryx Inc
09/08/202207:30GlobeNewswire Inc.ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference CallNASDAQ:CCXIChemoCentryx Inc
04/08/202208:12Dow Jones NewsChemoCentryx Shares Soar Premarket on Amgen Takeover DealNASDAQ:CCXIChemoCentryx Inc
04/08/202207:00PR Newswire (US)AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASHNASDAQ:CCXIChemoCentryx Inc
02/08/202215:05GlobeNewswire Inc.ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022NASDAQ:CCXIChemoCentryx Inc
05/07/202207:30GlobeNewswire Inc.ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent DirectorNASDAQ:CCXIChemoCentryx Inc
06/06/202209:15TipRanksH.C. Wainwright Sticks to Its Buy Rating for ChemoCentryx (CCXI)NASDAQ:CCXIChemoCentryx Inc
06/06/202207:30GlobeNewswire Inc.ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:CCXIChemoCentryx Inc
31/05/202215:05GlobeNewswire Inc.ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology ConferencesNASDAQ:CCXIChemoCentryx Inc
31/05/202207:30GlobeNewswire Inc.ChemoCentryx Announces Changes to its Board of DirectorsNASDAQ:CCXIChemoCentryx Inc
22/05/202203:46TipRanksCan ChemoCentryx Control Challenging Capital Complications?NASDAQ:CCXIChemoCentryx Inc
18/05/202207:30GlobeNewswire Inc.ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis SuppurativaNASDAQ:CCXIChemoCentryx Inc
16/05/202207:30GlobeNewswire Inc.ChemoCentryx to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:CCXIChemoCentryx Inc
11/05/202207:30GlobeNewswire Inc.ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated VasculitisNASDAQ:CCXIChemoCentryx Inc
10/05/202215:35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CCXIChemoCentryx Inc
09/05/202202:26TipRanksRaymond James Maintains Their Buy Rating on ChemoCentryx (CCXI)NASDAQ:CCXIChemoCentryx Inc
08/05/202221:18TipRanksChemoCentryx (CCXI) Receives a Buy from Stifel NicolausNASDAQ:CCXIChemoCentryx Inc
 Showing the most relevant articles for your search:NASDAQ:CCXI

Su Consulta Reciente

AMEX
XLF
Financial Select Sector
NYSE
MRK
Merck
CCOM
US30
US 30
USOTC
BASFY
BASF (QX)
NYSE
AXP
American Express
CCOM
OILBRENT
Brent Oil
NYSE
MCD
McDonalds
NASDAQ
AAPL
Apple
NYSE
JPM
JP Morgan Chase
AMEX
SPY
SPDR S&P 500
NYSE
CVX
Chevron
NASDAQ
GOOGL
Alphabet
COIN
BTCUSD
Bitcoin
USOTC
BNPQY
BNP Paribas (QX)
NYSE
NKE
Nike
FX
USDMXN
US Dollar vs MXN
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados